Cargando…

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

BACKGROUND: We sought to identify patient subgroups with distinct postprogression overall survival (ppOS) outcomes and investigate the impact of original treatment assignment and initial postprogression treatment (ppRx) on ppOS. METHODS: Recursive partitioning analysis (RPA) was performed to model r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ascierto, Paolo A., Ribas, Antoni, Larkin, James, McArthur, Grant A., Lewis, Karl D., Hauschild, Axel, Flaherty, Keith T., McKenna, Edward, Zhu, Qian, Mun, Yong, Dréno, Brigitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397682/ https://www.ncbi.nlm.nih.gov/pubmed/32746839 http://dx.doi.org/10.1186/s12967-020-02458-x

Ejemplares similares

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM
por: Lewis, Karl D., et al.
Publicado: (2019)

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF(V600) Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
por: Ascierto, Paolo A., et al.
Publicado: (2021)

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation–positive melanoma
por: Dréno, Brigitte, et al.
Publicado: (2018)

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF(V600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)
por: Ascierto, Paolo A, et al.
Publicado: (2015)

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study
por: de la Cruz-Merino, Luis, et al.
Publicado: (2017)

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma
por: Yan, Yibing, et al.
Publicado: (2014)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7)
por: Puzanov, Igor, et al.
Publicado: (2014)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
por: Álamo, Mª del Carmen, et al.
Publicado: (2021)

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
por: Simeone, Ester, et al.
Publicado: (2021)

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
por: Chapman, P B, et al.
Publicado: (2017)

Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma
por: Cai, Chao, et al.
Publicado: (2021)

Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report
por: Iafolla, Marco AJ, et al.
Publicado: (2019)

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials
por: Hopkins, Ashley M., et al.
Publicado: (2020)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Vemurafenib- and Cobimetinib-Associated Drug Reaction With Eosinophilia and Systemic Symptoms in a Patient With Metastatic Melanoma
por: Al-Saedy, Miriam, et al.
Publicado: (2023)

The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib
por: Medina, Theresa M, et al.
Publicado: (2016)

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
por: Fisher, Rosalie, et al.
Publicado: (2012)

OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility
por: Cabanillas, Maria, et al.
Publicado: (2019)

Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model
por: Kawaguchi, Kei, et al.
Publicado: (2016)

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature
por: van Berge Henegouwen, J. M., et al.
Publicado: (2022)

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
por: Daud, Adil, et al.
Publicado: (2017)

SK119, a Novel Shikonin Derivative, Leads to Apoptosis in Melanoma Cell Lines and Exhibits Synergistic Effects with Vemurafenib and Cobimetinib
por: Kretschmer, Nadine, et al.
Publicado: (2022)

Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma
por: BATINAC, Tanja, et al.
Publicado: (2022)

Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF(V600) melanoma cells
por: Smith, Lorey K., et al.
Publicado: (2020)

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
por: Krens, Stefanie D., et al.
Publicado: (2020)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
por: Żołek, Teresa, et al.
Publicado: (2023)

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
por: Kähler, Katharina C., et al.
Publicado: (2021)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection
por: Sondermann, Wiebke, et al.
Publicado: (2015)

Dupuytren’s contractures associated with the BRAF inhibitor vemurafenib: a case report
por: Chan, Sze Wai, et al.
Publicado: (2015)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
por: Aylwin, Simon J. B., et al.
Publicado: (2015)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_9sp8qreq2pf32lsreiqr6q36eu